[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$faoFn_7KS1tAYbAEv7wcHLYIkP8mhUILguEUCgt_iE3A":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":31,"phaseBuckets":47,"rows":54},"Hoag Memorial Hospital Presbyterian",[4],31,false,5,0,12486,3,13,[14,16,18,20,22,24,26,29],{"name":15,"count":8},"Lymphoma",{"name":17,"count":11},"Melanoma (Skin)",{"name":19,"count":11},"Leukemia",{"name":21,"count":11},"Unspecified Adult Solid Tumor, Protocol Specific",{"name":23,"count":11},"Breast Cancer",{"name":25,"count":11},"Pancreatic Cancer",{"name":27,"count":28},"Kidney Cancer",2,{"name":30,"count":28},"Prostate Cancer",[32,37,42],{"nctId":33,"briefTitle":34,"date":35,"intervention":36},"NCT04700332","PyL in Patients With High Risk and Biochemically Recurrent Prostate Cancer","2022-07-15","DCFPyL PET\u002FCT",{"nctId":38,"briefTitle":39,"date":40,"intervention":41},"NCT06736054","A Phase I Trial of 61Cu-NODAGA-PSMA for Patients with Prostate Cancer","2025-03-31","Copper 61-PSMA PET\u002FCT",{"nctId":43,"briefTitle":44,"date":45,"intervention":46},"NCT07344220","Metastatic Non-Familial Adenocarcinoma Maintenance Therapy With DZ-002: Heptamine Carboxymethine Dye Conjugate","2028-11","DZ-002 - 5 mg\u002Fkg, 6 mg\u002Fkg, or 7 mg\u002Fkg",[48,49,50,51,52,53],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[55,78,101,122,204,250,288,314,332,350,368,395,421,439,457,475,500,518,543,561,579,597,615,633,651,669,695],{"intervention":36,"totalTrials":56,"cells":57},1,{"EARLY_PHASE1":58,"PHASE1":60,"PHASE2":62,"PHASE3":72,"PHASE4":74,"NA":76},{"trials":59,"activeCount":9},[],{"trials":61,"activeCount":9},[],{"trials":63,"activeCount":56,"soonestReadout":35},[64],{"nctId":33,"briefTitle":34,"status":65,"phases":66,"primaryCompletion":35,"completion":67,"start":68,"enrollment":69,"conditions":70,"interventions":71},"RECRUITING",[50],"2022-12-15","2021-02-01",184,[30],[36],{"trials":73,"activeCount":9},[],{"trials":75,"activeCount":9},[],{"trials":77,"activeCount":9},[],{"intervention":46,"totalTrials":56,"cells":79},{"EARLY_PHASE1":80,"PHASE1":82,"PHASE2":84,"PHASE3":95,"PHASE4":97,"NA":99},{"trials":81,"activeCount":9},[],{"trials":83,"activeCount":9},[],{"trials":85,"activeCount":56,"soonestReadout":45},[86],{"nctId":43,"briefTitle":44,"status":87,"phases":88,"primaryCompletion":45,"completion":89,"start":90,"enrollment":91,"conditions":92,"interventions":94},"ENROLLING_BY_INVITATION",[50],"2029-04","2026-01",39,[93,25],"Metastatic Pancreatic Adenocarcinoma",[46],{"trials":96,"activeCount":9},[],{"trials":98,"activeCount":9},[],{"trials":100,"activeCount":9},[],{"intervention":41,"totalTrials":56,"cells":102},{"EARLY_PHASE1":103,"PHASE1":105,"PHASE2":114,"PHASE3":116,"PHASE4":118,"NA":120},{"trials":104,"activeCount":9},[],{"trials":106,"activeCount":56,"soonestReadout":40},[107],{"nctId":38,"briefTitle":39,"status":65,"phases":108,"primaryCompletion":40,"completion":40,"start":109,"enrollment":110,"conditions":111,"interventions":113},[49],"2024-10-14",8,[112],"Prostate Adenocarcinoma",[41],{"trials":115,"activeCount":9},[],{"trials":117,"activeCount":9},[],{"trials":119,"activeCount":9},[],{"trials":121,"activeCount":9},[],{"intervention":123,"totalTrials":124,"cells":125},"recombinant interferon alfa",6,{"EARLY_PHASE1":126,"PHASE1":128,"PHASE2":130,"PHASE3":198,"PHASE4":200,"NA":202},{"trials":127,"activeCount":9},[],{"trials":129,"activeCount":9},[],{"trials":131,"activeCount":9},[132,146,156,169,182,189],{"nctId":133,"briefTitle":134,"status":135,"phases":136,"primaryCompletion":137,"completion":137,"start":138,"enrollment":9,"conditions":139,"interventions":140},"NCT00004039","Combination Chemotherapy Plus Interferon Alfa or Rituximab in Treating Patients With Stage III or Stage IV Lymphoma","WITHDRAWN",[50],"2000-01","1998-06",[15],[123,141,142,143,144,145],"rituximab","cyclophosphamide","doxorubicin hydrochloride","prednisone","vincristine sulfate",{"nctId":147,"briefTitle":148,"status":149,"phases":150,"primaryCompletion":137,"completion":137,"start":151,"enrollment":152,"conditions":153,"interventions":154},"NCT00003091","High-Dose Interferon Alfa and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer or Melanoma","COMPLETED",[50],"1996-01",40,[27,17],[155,123],"aldesleukin",{"nctId":157,"briefTitle":158,"status":149,"phases":159,"primaryCompletion":160,"completion":161,"start":162,"conditions":163,"interventions":168},"NCT00002504","Interleukin-2 Plus Interferon Alfa in Treating Adults With Metastatic Cancer",[50],"1998-02","1999-02","1992-08",[164,19,15,165,166,167,21],"Chronic Myeloproliferative Disorders","Multiple Myeloma and Plasma Cell Neoplasm","Myelodysplastic Syndromes","Precancerous\u002FNonmalignant Condition",[155,123],{"nctId":170,"briefTitle":171,"status":149,"phases":172,"primaryCompletion":151,"completion":161,"start":162,"conditions":173,"interventions":180},"NCT00002506","Isotretinoin Plus Interferon in Treating Patients With Recurrent Cancer",[50],[174,175,176,177,178,179],"Cervical Cancer","Esophageal Cancer","Head and Neck Cancer","Lung Cancer","Non-melanomatous Skin Cancer","Penile Cancer",[123,181],"isotretinoin",{"nctId":183,"briefTitle":184,"status":135,"phases":185,"primaryCompletion":186,"completion":186,"start":138,"enrollment":9,"conditions":187,"interventions":188},"NCT00004040","Monoclonal Antibody Therapy or Biological Therapy in Treating Patients With Chronic Lymphocytic Leukemia or Multiple Myeloma in Remission After Chemotherapy",[50],"1999-06",[19,165],[123,141],{"nctId":190,"briefTitle":191,"status":149,"phases":192,"primaryCompletion":137,"completion":137,"start":151,"enrollment":193,"conditions":194,"interventions":195},"NCT00002733","Biological Therapy in Treating Patients With Metastatic Cancer",[50],30,[27,17,21],[155,123,196,197],"therapeutic tumor infiltrating lymphocytes","cimetidine",{"trials":199,"activeCount":9},[],{"trials":201,"activeCount":9},[],{"trials":203,"activeCount":9},[],{"intervention":141,"totalTrials":8,"cells":205},{"EARLY_PHASE1":206,"PHASE1":208,"PHASE2":210,"PHASE3":244,"PHASE4":246,"NA":248},{"trials":207,"activeCount":9},[],{"trials":209,"activeCount":9},[],{"trials":211,"activeCount":9},[212,216,223,233,237],{"nctId":133,"briefTitle":134,"status":135,"phases":213,"primaryCompletion":137,"completion":137,"start":138,"enrollment":9,"conditions":214,"interventions":215},[50],[15],[123,141,142,143,144,145],{"nctId":217,"briefTitle":218,"status":135,"phases":219,"primaryCompletion":137,"completion":137,"start":220,"enrollment":9,"conditions":221,"interventions":222},"NCT00003605","Rituximab Plus Cyclophosphamide in Treating Patients With Indolent Stage III or Stage IV Non-Hodgkin's Lymphoma",[50],"1998-05",[15],[141,142],{"nctId":224,"briefTitle":225,"status":149,"phases":226,"primaryCompletion":227,"completion":228,"start":229,"conditions":230,"interventions":231},"NCT00049413","Combination Chemotherapy and Rituximab in Treating Patients With Chronic Lymphocytic Leukemia or Lymphocytic Lymphoma",[50],"2004-12","2005-12","2002-06",[19,15],[141,142,232],"pentostatin",{"nctId":183,"briefTitle":184,"status":135,"phases":234,"primaryCompletion":186,"completion":186,"start":138,"enrollment":9,"conditions":235,"interventions":236},[50],[19,165],[123,141],{"nctId":238,"briefTitle":239,"status":135,"phases":240,"primaryCompletion":137,"completion":137,"start":138,"enrollment":9,"conditions":241,"interventions":242},"NCT00003663","Rituximab and Dexamethasone in Treating Patients With Recurrent or Refractory Indolent Non-Hodgkin's Lymphoma",[50],[15],[141,243],"dexamethasone",{"trials":245,"activeCount":9},[],{"trials":247,"activeCount":9},[],{"trials":249,"activeCount":9},[],{"intervention":155,"totalTrials":251,"cells":252},4,{"EARLY_PHASE1":253,"PHASE1":255,"PHASE2":257,"PHASE3":282,"PHASE4":284,"NA":286},{"trials":254,"activeCount":9},[],{"trials":256,"activeCount":9},[],{"trials":258,"activeCount":9},[259,263,267,278],{"nctId":147,"briefTitle":148,"status":149,"phases":260,"primaryCompletion":137,"completion":137,"start":151,"enrollment":152,"conditions":261,"interventions":262},[50],[27,17],[155,123],{"nctId":157,"briefTitle":158,"status":149,"phases":264,"primaryCompletion":160,"completion":161,"start":162,"conditions":265,"interventions":266},[50],[164,19,15,165,166,167,21],[155,123],{"nctId":268,"briefTitle":269,"status":149,"phases":270,"primaryCompletion":271,"completion":272,"start":161,"enrollment":273,"conditions":274,"interventions":276},"NCT00331526","Cellular Adoptive Immunotherapy in Treating Patients With Glioblastoma Multiforme",[50],"2008-12","2012-04",83,[275],"Brain and Central Nervous System Tumors",[155,277],"therapeutic autologous lymphocytes",{"nctId":190,"briefTitle":191,"status":149,"phases":279,"primaryCompletion":137,"completion":137,"start":151,"enrollment":193,"conditions":280,"interventions":281},[50],[27,17,21],[155,123,196,197],{"trials":283,"activeCount":9},[],{"trials":285,"activeCount":9},[],{"trials":287,"activeCount":9},[],{"intervention":142,"totalTrials":11,"cells":289},{"EARLY_PHASE1":290,"PHASE1":292,"PHASE2":294,"PHASE3":308,"PHASE4":310,"NA":312},{"trials":291,"activeCount":9},[],{"trials":293,"activeCount":9},[],{"trials":295,"activeCount":9},[296,300,304],{"nctId":133,"briefTitle":134,"status":135,"phases":297,"primaryCompletion":137,"completion":137,"start":138,"enrollment":9,"conditions":298,"interventions":299},[50],[15],[123,141,142,143,144,145],{"nctId":217,"briefTitle":218,"status":135,"phases":301,"primaryCompletion":137,"completion":137,"start":220,"enrollment":9,"conditions":302,"interventions":303},[50],[15],[141,142],{"nctId":224,"briefTitle":225,"status":149,"phases":305,"primaryCompletion":227,"completion":228,"start":229,"conditions":306,"interventions":307},[50],[19,15],[141,142,232],{"trials":309,"activeCount":9},[],{"trials":311,"activeCount":9},[],{"trials":313,"activeCount":9},[],{"intervention":143,"totalTrials":56,"cells":315},{"EARLY_PHASE1":316,"PHASE1":318,"PHASE2":320,"PHASE3":326,"PHASE4":328,"NA":330},{"trials":317,"activeCount":9},[],{"trials":319,"activeCount":9},[],{"trials":321,"activeCount":9},[322],{"nctId":133,"briefTitle":134,"status":135,"phases":323,"primaryCompletion":137,"completion":137,"start":138,"enrollment":9,"conditions":324,"interventions":325},[50],[15],[123,141,142,143,144,145],{"trials":327,"activeCount":9},[],{"trials":329,"activeCount":9},[],{"trials":331,"activeCount":9},[],{"intervention":144,"totalTrials":56,"cells":333},{"EARLY_PHASE1":334,"PHASE1":336,"PHASE2":338,"PHASE3":344,"PHASE4":346,"NA":348},{"trials":335,"activeCount":9},[],{"trials":337,"activeCount":9},[],{"trials":339,"activeCount":9},[340],{"nctId":133,"briefTitle":134,"status":135,"phases":341,"primaryCompletion":137,"completion":137,"start":138,"enrollment":9,"conditions":342,"interventions":343},[50],[15],[123,141,142,143,144,145],{"trials":345,"activeCount":9},[],{"trials":347,"activeCount":9},[],{"trials":349,"activeCount":9},[],{"intervention":145,"totalTrials":56,"cells":351},{"EARLY_PHASE1":352,"PHASE1":354,"PHASE2":356,"PHASE3":362,"PHASE4":364,"NA":366},{"trials":353,"activeCount":9},[],{"trials":355,"activeCount":9},[],{"trials":357,"activeCount":9},[358],{"nctId":133,"briefTitle":134,"status":135,"phases":359,"primaryCompletion":137,"completion":137,"start":138,"enrollment":9,"conditions":360,"interventions":361},[50],[15],[123,141,142,143,144,145],{"trials":363,"activeCount":9},[],{"trials":365,"activeCount":9},[],{"trials":367,"activeCount":9},[],{"intervention":369,"totalTrials":56,"cells":370},"89Zr-daratumumab PET\u002FCT",{"EARLY_PHASE1":371,"PHASE1":373,"PHASE2":375,"PHASE3":389,"PHASE4":391,"NA":393},{"trials":372,"activeCount":9},[],{"trials":374,"activeCount":9},[],{"trials":376,"activeCount":9},[377],{"nctId":378,"briefTitle":379,"status":380,"phases":381,"primaryCompletion":382,"completion":383,"start":384,"enrollment":385,"conditions":386,"interventions":388},"NCT04814615","A Diagnostic Study of CD38-Targeted ImmunoPET of Myeloma","UNKNOWN",[50],"2026-01-31","2026-03-15","2021-03-08",60,[387],"Multiple Myeloma",[369],{"trials":390,"activeCount":9},[],{"trials":392,"activeCount":9},[],{"trials":394,"activeCount":9},[],{"intervention":396,"totalTrials":56,"cells":397},"autologous tumor cell vaccine",{"EARLY_PHASE1":398,"PHASE1":400,"PHASE2":402,"PHASE3":415,"PHASE4":417,"NA":419},{"trials":399,"activeCount":9},[],{"trials":401,"activeCount":9},[],{"trials":403,"activeCount":9},[404],{"nctId":405,"briefTitle":406,"status":149,"phases":407,"primaryCompletion":408,"completion":408,"start":409,"enrollment":410,"conditions":411,"interventions":412},"NCT00436930","Vaccine Therapy and GM-CSF in Treating Patients With Recurrent or Metastatic Melanoma",[50],"2012-10","2006-12",200,[17],[396,413,414],"sargramostim","therapeutic autologous dendritic cells",{"trials":416,"activeCount":9},[],{"trials":418,"activeCount":9},[],{"trials":420,"activeCount":9},[],{"intervention":413,"totalTrials":56,"cells":422},{"EARLY_PHASE1":423,"PHASE1":425,"PHASE2":427,"PHASE3":433,"PHASE4":435,"NA":437},{"trials":424,"activeCount":9},[],{"trials":426,"activeCount":9},[],{"trials":428,"activeCount":9},[429],{"nctId":405,"briefTitle":406,"status":149,"phases":430,"primaryCompletion":408,"completion":408,"start":409,"enrollment":410,"conditions":431,"interventions":432},[50],[17],[396,413,414],{"trials":434,"activeCount":9},[],{"trials":436,"activeCount":9},[],{"trials":438,"activeCount":9},[],{"intervention":414,"totalTrials":56,"cells":440},{"EARLY_PHASE1":441,"PHASE1":443,"PHASE2":445,"PHASE3":451,"PHASE4":453,"NA":455},{"trials":442,"activeCount":9},[],{"trials":444,"activeCount":9},[],{"trials":446,"activeCount":9},[447],{"nctId":405,"briefTitle":406,"status":149,"phases":448,"primaryCompletion":408,"completion":408,"start":409,"enrollment":410,"conditions":449,"interventions":450},[50],[17],[396,413,414],{"trials":452,"activeCount":9},[],{"trials":454,"activeCount":9},[],{"trials":456,"activeCount":9},[],{"intervention":181,"totalTrials":56,"cells":458},{"EARLY_PHASE1":459,"PHASE1":461,"PHASE2":463,"PHASE3":469,"PHASE4":471,"NA":473},{"trials":460,"activeCount":9},[],{"trials":462,"activeCount":9},[],{"trials":464,"activeCount":9},[465],{"nctId":170,"briefTitle":171,"status":149,"phases":466,"primaryCompletion":151,"completion":161,"start":162,"conditions":467,"interventions":468},[50],[174,175,176,177,178,179],[123,181],{"trials":470,"activeCount":9},[],{"trials":472,"activeCount":9},[],{"trials":474,"activeCount":9},[],{"intervention":476,"totalTrials":56,"cells":477},"Gallium-68 DOTATATE",{"EARLY_PHASE1":478,"PHASE1":480,"PHASE2":482,"PHASE3":494,"PHASE4":496,"NA":498},{"trials":479,"activeCount":9},[],{"trials":481,"activeCount":9},[],{"trials":483,"activeCount":9},[484],{"nctId":485,"briefTitle":486,"status":380,"phases":487,"primaryCompletion":488,"completion":488,"start":489,"enrollment":193,"conditions":490,"interventions":492},"NCT05880394","Study of Dotatate Imaging in Breast Cancer",[50],"2024-07-31","2023-01-10",[491],"Breast Cancer Stage IV",[476,493],"Copper-64 DOTATATE",{"trials":495,"activeCount":9},[],{"trials":497,"activeCount":9},[],{"trials":499,"activeCount":9},[],{"intervention":493,"totalTrials":56,"cells":501},{"EARLY_PHASE1":502,"PHASE1":504,"PHASE2":506,"PHASE3":512,"PHASE4":514,"NA":516},{"trials":503,"activeCount":9},[],{"trials":505,"activeCount":9},[],{"trials":507,"activeCount":9},[508],{"nctId":485,"briefTitle":486,"status":380,"phases":509,"primaryCompletion":488,"completion":488,"start":489,"enrollment":193,"conditions":510,"interventions":511},[50],[491],[476,493],{"trials":513,"activeCount":9},[],{"trials":515,"activeCount":9},[],{"trials":517,"activeCount":9},[],{"intervention":519,"totalTrials":56,"cells":520},"filgrastim",{"EARLY_PHASE1":521,"PHASE1":523,"PHASE2":525,"PHASE3":537,"PHASE4":539,"NA":541},{"trials":522,"activeCount":9},[],{"trials":524,"activeCount":9},[],{"trials":526,"activeCount":9},[527],{"nctId":528,"briefTitle":529,"status":149,"phases":530,"primaryCompletion":531,"completion":532,"start":162,"conditions":533,"interventions":534},"NCT00002505","Tumor Cell Vaccine in Treating Patients With Advanced Cancer",[50],"2002-08","2006-05",[21],[519,535,536],"recombinant interferon gamma","tumor cell lysate vaccine therapy",{"trials":538,"activeCount":9},[],{"trials":540,"activeCount":9},[],{"trials":542,"activeCount":9},[],{"intervention":535,"totalTrials":56,"cells":544},{"EARLY_PHASE1":545,"PHASE1":547,"PHASE2":549,"PHASE3":555,"PHASE4":557,"NA":559},{"trials":546,"activeCount":9},[],{"trials":548,"activeCount":9},[],{"trials":550,"activeCount":9},[551],{"nctId":528,"briefTitle":529,"status":149,"phases":552,"primaryCompletion":531,"completion":532,"start":162,"conditions":553,"interventions":554},[50],[21],[519,535,536],{"trials":556,"activeCount":9},[],{"trials":558,"activeCount":9},[],{"trials":560,"activeCount":9},[],{"intervention":536,"totalTrials":56,"cells":562},{"EARLY_PHASE1":563,"PHASE1":565,"PHASE2":567,"PHASE3":573,"PHASE4":575,"NA":577},{"trials":564,"activeCount":9},[],{"trials":566,"activeCount":9},[],{"trials":568,"activeCount":9},[569],{"nctId":528,"briefTitle":529,"status":149,"phases":570,"primaryCompletion":531,"completion":532,"start":162,"conditions":571,"interventions":572},[50],[21],[519,535,536],{"trials":574,"activeCount":9},[],{"trials":576,"activeCount":9},[],{"trials":578,"activeCount":9},[],{"intervention":232,"totalTrials":56,"cells":580},{"EARLY_PHASE1":581,"PHASE1":583,"PHASE2":585,"PHASE3":591,"PHASE4":593,"NA":595},{"trials":582,"activeCount":9},[],{"trials":584,"activeCount":9},[],{"trials":586,"activeCount":9},[587],{"nctId":224,"briefTitle":225,"status":149,"phases":588,"primaryCompletion":227,"completion":228,"start":229,"conditions":589,"interventions":590},[50],[19,15],[141,142,232],{"trials":592,"activeCount":9},[],{"trials":594,"activeCount":9},[],{"trials":596,"activeCount":9},[],{"intervention":277,"totalTrials":56,"cells":598},{"EARLY_PHASE1":599,"PHASE1":601,"PHASE2":603,"PHASE3":609,"PHASE4":611,"NA":613},{"trials":600,"activeCount":9},[],{"trials":602,"activeCount":9},[],{"trials":604,"activeCount":9},[605],{"nctId":268,"briefTitle":269,"status":149,"phases":606,"primaryCompletion":271,"completion":272,"start":161,"enrollment":273,"conditions":607,"interventions":608},[50],[275],[155,277],{"trials":610,"activeCount":9},[],{"trials":612,"activeCount":9},[],{"trials":614,"activeCount":9},[],{"intervention":196,"totalTrials":56,"cells":616},{"EARLY_PHASE1":617,"PHASE1":619,"PHASE2":621,"PHASE3":627,"PHASE4":629,"NA":631},{"trials":618,"activeCount":9},[],{"trials":620,"activeCount":9},[],{"trials":622,"activeCount":9},[623],{"nctId":190,"briefTitle":191,"status":149,"phases":624,"primaryCompletion":137,"completion":137,"start":151,"enrollment":193,"conditions":625,"interventions":626},[50],[27,17,21],[155,123,196,197],{"trials":628,"activeCount":9},[],{"trials":630,"activeCount":9},[],{"trials":632,"activeCount":9},[],{"intervention":197,"totalTrials":56,"cells":634},{"EARLY_PHASE1":635,"PHASE1":637,"PHASE2":639,"PHASE3":645,"PHASE4":647,"NA":649},{"trials":636,"activeCount":9},[],{"trials":638,"activeCount":9},[],{"trials":640,"activeCount":9},[641],{"nctId":190,"briefTitle":191,"status":149,"phases":642,"primaryCompletion":137,"completion":137,"start":151,"enrollment":193,"conditions":643,"interventions":644},[50],[27,17,21],[155,123,196,197],{"trials":646,"activeCount":9},[],{"trials":648,"activeCount":9},[],{"trials":650,"activeCount":9},[],{"intervention":243,"totalTrials":56,"cells":652},{"EARLY_PHASE1":653,"PHASE1":655,"PHASE2":657,"PHASE3":663,"PHASE4":665,"NA":667},{"trials":654,"activeCount":9},[],{"trials":656,"activeCount":9},[],{"trials":658,"activeCount":9},[659],{"nctId":238,"briefTitle":239,"status":135,"phases":660,"primaryCompletion":137,"completion":137,"start":138,"enrollment":9,"conditions":661,"interventions":662},[50],[15],[141,243],{"trials":664,"activeCount":9},[],{"trials":666,"activeCount":9},[],{"trials":668,"activeCount":9},[],{"intervention":670,"totalTrials":56,"cells":671},"Autologous tumor cells plus dendritic cells",{"EARLY_PHASE1":672,"PHASE1":674,"PHASE2":676,"PHASE3":689,"PHASE4":691,"NA":693},{"trials":673,"activeCount":9},[],{"trials":675,"activeCount":9},[],{"trials":677,"activeCount":9},[678],{"nctId":679,"briefTitle":680,"status":149,"phases":681,"primaryCompletion":682,"completion":682,"start":683,"enrollment":684,"conditions":685,"interventions":687},"NCT00948480","Vaccine Biotherapy of Cancer: Autologous Tumor Cells and Dendritic Cells",[50],"2007-09","2000-10",56,[686],"Metastatic Melanoma",[670,688],"GM-CSF",{"trials":690,"activeCount":9},[],{"trials":692,"activeCount":9},[],{"trials":694,"activeCount":9},[],{"intervention":688,"totalTrials":56,"cells":696},{"EARLY_PHASE1":697,"PHASE1":699,"PHASE2":701,"PHASE3":707,"PHASE4":709,"NA":711},{"trials":698,"activeCount":9},[],{"trials":700,"activeCount":9},[],{"trials":702,"activeCount":9},[703],{"nctId":679,"briefTitle":680,"status":149,"phases":704,"primaryCompletion":682,"completion":682,"start":683,"enrollment":684,"conditions":705,"interventions":706},[50],[686],[670,688],{"trials":708,"activeCount":9},[],{"trials":710,"activeCount":9},[],{"trials":712,"activeCount":9},[]]